To identify LSC-specific vulnerabilities, we characterized LSCs (CD34+ CD90– CD38–) and leukemic blasts (CD34+ CD90– CD38+) purified from a CEBPAN/C AML sample expressing both C/EBPα isoforms (Supplementary Fig. S6A–C). The gene discussed is CEBPA; the disease is acute myeloid leukemia.